Biovista Inc. announces positive efficacy results in a pre-clinical trial of BVA-101 for Multiple Sclerosis

April 2, 2009Press Releases

CHARLOTTESVILLE, Virginia, April 2 /PRNewswire/ — Biovista Inc. today announced that BVA-101, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-101, an existing drug that Biovista repositioned in MS and is aimed at neuroprotection, was shown to have both efficacy in … Read More